About: Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
Creator	Hou, Hongyan Sun, Ziyong Zhang, Bo Wang, Feng Wang, Ting Luo, Ying Wu, Shiji Mao, Lie
Source	Medline; PMC; WHO
abstract	OBJECTIVES: This study aimed to determine the IgM and IgG responses against severe acute respiratory syndrome coronavirus (SARS‐CoV)‐2 in coronavirus disease 2019 (COVID‐19) patients with varying illness severities. METHODS: IgM and IgG antibody levels were assessed via chemiluminescence immunoassay in 338 COVID‐19 patients. RESULTS: IgM levels increased during the first week after SARS‐CoV‐2 infection, peaked 2 weeks and then reduced to near‐background levels in most patients. IgG was detectable after 1 week and was maintained at a high level for a long period. The positive rates of IgM and/or IgG antibody detections were not significantly different among the mild, severe and critical disease groups. Severe and critical cases had higher IgM levels than mild cases, whereas the IgG level in critical cases was lower than those in both mild and severe cases. This might be because of the high disease activity and/or a compromised immune response in critical cases. The IgM antibody levels were slightly higher in deceased patients than recovered patients, but IgG levels in these groups did not significantly differ. A longitudinal detection of antibodies revealed that IgM levels decreased rapidly in recovered patients, whereas in deceased cases, either IgM levels remained high or both IgM and IgG were undetectable during the disease course. CONCLUSION: Quantitative detection of IgM and IgG antibodies against SARS‐CoV‐2 quantitatively has potential significance for evaluating the severity and prognosis of COVID‐19.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1002/cti2.1136
bibo:pmid	32382418
has license	cc-by
sha1sum (hex)	0cae7a4ca7c3097fbc64b85e61756566fbbf2c98
schema:url	https://doi.org/10.1002/cti2.1136
resource representing a document's title	Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
has PubMed Central identifier	PMC7202656
has PubMed identifier	32382418
schema:publication	Clin Transl Immunology
resource representing a document's body	covid:0cae7a4ca7c3097fbc64b85e61756566fbbf2c98#body_text
is schema:about of	named entity 'severe acute respiratory syndrome coronavirus' named entity 'undetectable' named entity 'detection' named entity 'cases' named entity 'groups' named entity 'IgG' named entity 'patients' named entity 'patients' covid:arg/0cae7a4ca7c3097fbc64b85e61756566fbbf2c98 named entity 'cases' named entity 'IgG' named entity 'IgG' named entity 'peaked' named entity 'IgM' named entity 'patients' named entity 'patients' named entity 'levels' named entity 'coronavirus disease 2019' named entity 'compromised' named entity 'study' named entity 'cases' named entity 'disease' named entity 'prognosis' named entity 'severe' named entity 'levels' named entity 'chemiluminescence' named entity 'immunoassay' named entity 'prognosis' named entity 'COVID' named entity 'IgG' named entity 'IgM' named entity 'IgG' named entity 'IgG' named entity 'COVID-19' named entity 'IgM' named entity 'immune response' named entity 'IgG antibodies' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'expectoration' named entity 'multiple organ dysfunction' named entity 'serum' named entity 'Tongji Medical College' named entity 'antibody' named entity 'infection' named entity 'cardiovascular diseases' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'COVID' named entity 'symptom' named entity 'immune response' named entity 'Tongji Hospital' named entity 'throat swab' named entity 'transport medium' named entity 'inflammatory responses' named entity 'IgM' named entity 'Tongji Hospital' named entity 'symptom' named entity 'public health emergency of international concern' named entity 'COVID' named entity 'antibodies' named entity 'IgG' named entity 'antibody' named entity 'IgM' named entity '15.6' named entity 'IgM' named entity 'San Diego' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'IgG' named entity 'spike protein' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software